All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Merck Sharp & Dohme LLC
Enrolment target
420
Start
24 Jan 2023
What is this study about?
Overall Survival (OS), Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR)
Who may be eligible?
Age 18 Years to any · Sex: Male
Locations (11)
- —Austria
- —Italy
- —Netherlands
- —Germany
- —Hungary
- —Ireland
- —Spain
- —Bulgaria
- —Czechia
- —Poland
- —France
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.